Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects

Annals of Clinical and Laboratory Science

Volumn 39, Issue 3, 2009, Pages 251-262

  Karaczyn, Aldona A ^a   Cheng, Robert Y S ^a   Buzard, Gregory S ^b   Hartley, James ^b   Esposito, Dominic ^b   Kasprzak, Kazimierz S ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Maine Medical Center Research Institute   (United States)

Author keywords

Cancer related genes; Gene expression; Histone H2A; Nickel carcinogenesis

Indexed keywords

CLAUDIN 18; CYTOCHROME P450 1A1; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE H2A; INTERFERON REGULATORY FACTOR 7; JANUS KINASE 3; LENS EPITHELIUM DERIVED GROWTH FACTOR; NICKEL; NONHISTONE PROTEIN; PDZ PROTEIN; PROTEIN BAZ2A; PROTEIN GIPC2; PROTEIN PSIP1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL FREE SYSTEM; CHROMATIN STRUCTURE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROLYSIS; KIDNEY CELL; MICROARRAY ANALYSIS; MULTIDIMENSIONAL SCALING; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; CELL LINE; CLUSTER ANALYSIS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONES; HUMANS; HYDROLYSIS; NEOPLASMS; NICKEL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

ANIMALIA;

EID: 68949159909     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. 2, a peptide modeling the potential metal binding site in the "C-Tail" region of histone H2A. Chem Res Toxicol 1998;11:1014-1023.
2. Karaczyn AA, Bal W, North SL, et al. The octapeptidic end of the C-terminal tail of histone H2A is cleaved off in cells exposed to carcinogenic nickel(II). Chem Res Toxicol 2003;16:1555-1559. (Pubitemid 38049375)
3. Bal W, Liang R, Lukszo J, et al. Ni(II) specifically cleaves the C-terminal tail of the major variant of histone H2A and forms an oxidative damage-mediating complex with the cleaved-off octapeptide. Chem Res Toxicol 2000;13:616-624. (Pubitemid 30491123)
4. Kamakaka RT, Biggins S. Histone variants: deviants? Genes Dev 2005;19:295-310.
5. Arya G, Schlick T. Role of histone tails in chromatin folding revealed by a mesoscopic oligonucleosome model. PNAS USA 2006;103:16236-16241. (Pubitemid 44715180)
6. Angelov D, Vitolo JM, Mutskov V, et al. Preferential interaction of the core histone tail domains with linker DNA. PNAS USA 2001;98:6599-6604. (Pubitemid 32538262)
7. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-294. (Pubitemid 29380564)
8. Ausio J, Abbott DW, Wang X, Moore SC. Histone variants and histone modifications: a structural perspective. Biochem Cell Biol 2001;79:693-708. (Pubitemid 34056593)
9. Zhang Y. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev 2003;17:2733-2740. (Pubitemid 37463282)
10. Nathan D, Sterner DE, Berger SL. Histone modifications: Now summoning sumoylation. PNAS USA 2003;100:13118-13120. (Pubitemid 37444703)
11. Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. PNAS USA 2003;100:13225-13230. (Pubitemid 37444723)
12. Khan AU, Krishnamurthy S. Histone modifications as key regulators of transcription. Front Biosci 2005;10:866-872.
13. Bartova E, Krejci J, Harnicarova A, et al. Histone modifications and nuclear architecture: a review. J Histochem Cytochem 2008;56:711-721. (Pubitemid 351991084)
14. Placek BJ, Gloss LM. The N-terminal tails of the H2A-H2B histones affect dimer structure and stability. Biochemistry 2002;41:14960-14968.
15. Eickbush TH, Godfrey JE, Elia MC, Moudrianakis EN. H2a-specific proteolysis as a unique probe in the analysis of the histone octamer. J Biol Chem 1988;263:18972-18978.
16. Usachenko SI, Bavykin SG, Gavin IM, Bradbury EM. Rearrangement of the histone H2A C-terminal domain in the nucleosome. PNAS USA 1994;91:6845-6849.
17. Hartley JL, Temple GF, Brasch MA. DNA cloning using in vitro site-specific recombination. Genome Res 2000;10:1788-1795.
18. Campbell RE, Tour O, Palmer AE et al. A monomeric red fluorescent protein. PNAS USA 2002;99:7877-7882.
19. Ivanova VS, Bonner WM. Expression of a marked H2A histone protein in mammalian cells. Exp Cell Res 1994;215:63-67.
20. Bonner WM, West MH, Stedman JD. Two-dimensional gel analysis of histones in acid extracts of nuclei, cells, and tissues. Eur J Biochem 1980;109:17-23.
21. Reeves R, Gorman CM, Howard B. In vivo incorporation of Drosophila H2a histone into mammalian chromatin. Nucleic Acids Res 1983;11:2681-2700.
22. Eickbush TH, Watson DK, Moudrianakis EN. A chromatin-bound proteolytic activity with unique specificity for histone H2A. Cell 1976;9:785-792.
23. Minami J, Takada K, Aoki K, et al. Purification and characterization of C-terminal truncated forms of histone H2A in monocytic THP-1 cells. Int J Biochem Cell Biol 2007;39:171-180. (Pubitemid 44548444)
24. Furlan M, Jericijo M, Suhar A. Purification and properties of a neutral protease from alf thymus nuclei. Biochim Biophys Acta 1968;167:154-160.
25. Chong MT, Garrard WT, Bonner J. Purification and properties of a neutral protease from rat liver chromatin. Biochemistry 1974;13:5128-5134.
26. Furuya M, Yonemitsu Y. Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 2008;8:253-265.
27. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med 2008;14:476-484.
28. Hopfer SM, Sunderman FW Jr, McCully KS, et al. Studies of the pathogenesis of arteriosclerosis induced in rats by intrarenal injection of a carcinogen, nickel subsulfide. Ann Clin Lab Sci 1984;14:355-365.
29. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005;11:7369-7375. (Pubitemid 41507696)
30. Kumarakulasingham M, Rooney PH, Dundas SR, et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 2005;11:3758-3765. (Pubitemid 40685593)
31. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006;6:186. (Pubitemid 46277109)
32. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008;32:188-196. (Pubitemid 351172132)
33. Sanada Y, Oue N, Mitani Y, et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 2006;208:633-642.
34. Daugaard M, Kirkegaard-Sorensen T, Ostenfeld MS, et al. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res 2007;67:2559-2567. (Pubitemid 46548941)
35. Knoops L, Hornakova T, Royer Y, et al. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008;27:1511-1519. (Pubitemid 351347883)
36. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 2003;22:423-434.
37. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20:1759-1766. (Pubitemid 44574987)
38. Kirikoshi H, Katoh M. Up-regulation of GIPC2 in human gastric cancer. Int J Oncol 2002;20:1183-1187.
39. Katoh M. GIPC gene family (Review). Int J Mol Med 2002;9:585-589.
40. Kirikoshi H, Katoh M. Molecular cloning and characterization of human GIPC2, a novel gene homologous to human GIPC1 and Xenopus Kermit. Int J Oncol 2002;20:571-576.
41. Jones MH, Hamana N, Nezu J, Shimane M. A novel family of bromodomain genes. Genomics 2000;63:40-45.
42. Panagopoulos I, Strombeck B, Isaksson M, et al. Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol 2006;133:270-275.
43. Rebhun JF, Castro AF, Quilliam LA. Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase. Regulation of MR-GEF by M-Ras-GTP interaction. J Biol Chem 2000;275:34901-34908.
44. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta 2008;1786:178-187.
45. Zhang L, Zhang J, Lambert Q, et al. Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol 2004;78:12987-12995. (Pubitemid 39507806)
46. Zhang L, Pagano JS. Structure and function of IRF-7. J Interferon Cytokine Res 2002;22:95-101.
47. Fukasawa M, Kimura M, Morita S, et al. Microarray analysis of promoter methylation in lung cancers. J Hum Genet 2006;51:368-374.
48. Ausio J, Abbott DW. The many tales of a tail: carboxyl-terminal tail heterogeneity specializes histone H2A variants for defined chromatin function. Biochemistry 2002;41:5945-5949. (Pubitemid 34498898)
49. Kasprzak KS, Sunderman FW Jr, Salnikow K. Nickel carcinogenesis. Mutat Res 2003;533:67-97.
50. Salnikow K, Kasprzak KS. Ascorbate depletion: a critical step in nickel carcinogenesis? Environ Health Perspect 2005;113:577-584.
51. Lee SH, Shiao YH, Plisov SY, Kasprzak KS. Nickel(II) acetate-treated Chinese hamster ovary cells differentially express Vimentin, hSNF2H homologue, and H ferritin. Biochem Biophys Res Commun 1999;258:592-595.
52. Xie R, van Wijnen AJ, van Der Meijden C, et al. The cell cycle control element of histone H4 gene transcription is maximally responsive to interferon regulatory factor pairs IRF-1/IRF-3 and IRF-1/IRF-7. J Biol Chem 2001;276:18624-18632. (Pubitemid 37411443)
53. Cheng RY, Zhao A, Alvord WG, et al. Gene expression dose-response changes in microarrays after exposure of human peripheral lung epithelial cells to nickel(II). Toxicol Appl Pharmacol 2003;191:22-39. (Pubitemid 36959961)
54. Navaratnam N, Sarwar R. An overview of cytidine deaminases. Int J Hematol 2006;83:195-200.
55. Lethe B, Lucas S, Michaux L, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998;76:903-908. (Pubitemid 28262112)
56. Rouzaut A, Recio JA, Notario V. Expression of the protein product of the PCPH proto-oncogene in human tumor cell lines. Radiat Res 2001;155:181-187. (Pubitemid 33723536)
57. Blanquez MJ, Arenas MI, Conde I, et al. Deregulated expression of the PCPH proto-oncogene in human breast cancers. Int J Oncol 2004;25:821-830.
58. Blanquez MJ, Regadera J, Marino J, et al. Gradual deregulation and loss of PCPH expression in the progression of human laryngeal neoplasia. Mol Carcinog 2002;35:186-195. (Pubitemid 36056713)
59. Eichberger T, Regl G, Ikram MS, et al. FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004;122:1180-1187. (Pubitemid 38651093)
60. la Cour JM, Mollerup J, Winding P, et al. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol 2003;163:81-89. (Pubitemid 36759593)
61. 2+-binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta 2002;1600:68-73.
62. Yotov WV, Hamel H, Rivard GE, et al. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer 1999;26:62-69. (Pubitemid 29374864)
63. Cho JM, Song DJ, Bergeron J, et al. RBT1, a novel transcriptional co-activator, binds the second subunit of replication protein A. Nucleic Acids Res 2000;28:3478-3485.
64. Domoto T, Miyama Y, Suzuki H, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 2007;98:77-82. (Pubitemid 44803923)
65. Stankovic-Valentin N, Deltour S, Seeler J, et al. An acetylation/ deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol 2007;27:2661-2675. (Pubitemid 46581356)
66. Phillips SA, Barr VA, Haft DH, et al. Identification and characterization of SNX15, a novel sorting nexin involved in protein trafficking. J Biol Chem 2001;276:5074-5084. (Pubitemid 37371401)
67. Muller S, van den Boom D, Zirkel D, et al. Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors. Hum Mol Genet 2000;9:757-763. (Pubitemid 30162759)
68. Schwienbacher C, Angioni A, Scelfo R, et al. Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumor. Cancer Res 2000;60:1521-1525. (Pubitemid 30183418)
69. McRory JE, Hamid J, Doering CJ, et al. The CACNA1F gene encodes an L-type calcium channel with unique biophysical properties and tissue distribution. J Neurosci 2004;24:1707-1718. (Pubitemid 38240968)
70. Wang H, Arun BK, Wang H, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 2008;14:261-267. (Pubitemid 351678058)
71. Takatsu H, Futatsumori M, Yoshino K, et al. Similar subunit interactions contribute to assembly of clathrin adaptor complexes and COPI complex: analysis using yeast three-hybrid system. Biochem Biophys Res Commun 2001;284:1083-1089. (Pubitemid 32924759)
72. Kominsky SL. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006;8:1-11. (Pubitemid 44184255)
73. Dhawan P, Singh AB, Deane NG, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005;115:1765-1776. (Pubitemid 40979715)
74. Weitzdoerfer R, Fountoulakis M, Lubec G. Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain. J Neural Transm Suppl 2001;95-107. (Pubitemid 38085075)
75. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005;11:226-231. (Pubitemid 40075799)
76. Abraham S, Knapp DW, Cheng L, et al. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006;12:353-360. (Pubitemid 43166121)
77. Lu C, Shahzad MM, Wang H, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008;7:1098-1103.
78. Xiao D, Wang K, Zhou J, et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2008;40:297-303. (Pubitemid 351572110)
79. Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008;39:365-372.
80. Nemos C, Mansuy V, Vernier-Magnin S, et al. Expression of gec1/GABARAPL1 versus GABARAP mRNAs in human: predominance of gec1/GABARAPL1 in the central nervous system. Brain Res Mol Brain Res 2003;119:216-219. (Pubitemid 37415096)
81. Weigelt B, Bosma AJ, van 't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol 2003;129:735-736. (Pubitemid 38002305)
82. Xu J, Zhou Z, Zeng L, et al. Cloning, expression and characterization of a novel human REPS1 gene. Biochim Biophys Acta 2001;1522:118-121. (Pubitemid 34028213)
83. Katoh M, Katoh M. Identification and characterization of human GUKH2 gene in silico. Int J Oncol 2004;24:1033-1038.
84. Tan M, Gu Q, He H, et al. SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1 alpha ubiquitination and degradation. Oncogene 2008;27:1404-1411. (Pubitemid 351317467)
85. Selvakumar P, Lakshmikuttyamma A, Dimmock JR, Sharma RK. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta 2006;1765:148-154.
86. Kveberg L, Ryan JC, Rolstad B, Inngjerdingen M. Expression of regulator of G protein signalling proteins in natural killer cells, and their modulation by Ly49A and Ly49D. Immunology 2005;115:358-365. (Pubitemid 40896034)
87. Sood R, Bonner TI, Makalowska I, et al. Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics 2001;73:211-222. (Pubitemid 32411358)